Actions Developing in Countries Accessing the WTO System Vung Tau, 20-21 February 2006 “US – Brazil Compulsory licensing.

Slides:



Advertisements
Similar presentations
Caribbean Central American Action (CCAA) Strengthening in the Third Border (CBI) CCA 27 th Annual Miami Conference on the Caribbean Basin Dr Rosanna Cooper,
Advertisements

Intellectual property rights and procurement = international developments & national experiences = Bi-regional Workshop on procurement and supply management.
Durban, South Africa January 29 to 31, 2013 Topic 8: Compulsory Licenses Regional Seminar for Certain African Countries on the Implementation and Use of.
The TRIPS Agreement and Public Health
1 WTO and medicines: from Doha to Cancún Germán Velásquez Essential Drugs and Medicines Policy World Health Organization Geneva, October 2003.
Agreement on TRIPS & access to medicines Presentation by Dr Zafar Mirza PILdAT Briefing session for Parliamentarians on “The WTO Regime and Implications.
Understanding patents & medicine access the WTO, free trade agreements & patent law.
J.P. Singh Georgetown University Communication, Culture, & Technology Program TRIPS: Negotiating Intellectual Property in the World Trading System J.
The Global Access to Medicines Movement Peter Maybarduk April 15, 2011.
Benjamin Blasco Anna Ferretti Sophie Venet BIO615 Fall 2009.
Ato2461 INTELLECTUAL PROPERTY AND DEVELOPMENT Presentation by Adrian Otten Director, Intellectual Property Division, WTO Secretariat Panel Discussion 7.
Challenges and Opportunities to Utilize TRIPS Flexibilities in Current Ukrainian Legislation: Potential Impact of IP Provisions in the Proposed EU FTA.
Medicine Access: Claims & Data Sanjay Basu. The Framework for Access The pipeline fallacy Patents and pricing.
A revised framework for global medicine access Sanjay Basu Reblaw X.
Greedy Sleazy Patent Owners vs. Poor Sick People International Patent Protection and Access to Drugs in the Third World Liz Durham November 4, 2003.
Intellectual Property Rights, Services and Trade Facilitation CARSTEN FINK African/LDCs Ambassadors Seminar on Post-Hong Kong Assessment of the Doha Round,
IP News 指導老師:李柏靜 學生:黃馨葦 M /3/26.  Citing the high cost of one of the pharmaceutical industry's expensive new cancer drugs, India's patent.
1 ICC and AIPLA Paris, September 13, 2002 Felix Addor Chief Legal Officer and Deputy Director General Swiss Federal Institute of Intellectual Property.
Intellectual Property and Access to Affordable Medicines: TRIPS Plus
1 Intellectual Property Rights in Medicines Procurement Patrick Osewe Senior HIV/AIDS Specialist World Bank.
A very short introduction to patents & access to medicines.
TRIPS flexibilities and examples which resulted in reduced medicine prices: Model legislation and compulsory licensing in Brazil Juliana V. Borges Vallini.
SAREE AONGSOMWANG Foundation for Consumers, Thailand.
Patent Related Flexibilities in the Pharmaceutical Field
FLEXIBILITIES IN WTO’S TRIPS AGREEMENT FOR ACCESS TO MEDICINES
Issues Pertinent for Action in the South Presentation to Partners in Population and Development: Meeting on Accelerating Essential Health Commodity Security.
Why is protecting pharmaceutical patents a controversial issue in DCs? Poor DCs can neither produce nor afford to buy patented drugs. They need generic.
TRIPS, Doha and Access to Medicines: Recent Lessons CARSTEN FINK Globalization, Intellectual Property Rights and Social Equity: Challenges and Opportunities.
PATENTS AND HEALTH. A CASE STUDY OF THE UGANDAN CONTEXT. (PHA3 JULY 7 TH 2012 –CAPE TOWN, SOUTH AFRICA) MS. MARIAM AKIROR LLB (HONS) / DIP. SW / CPC. PROG.
Patents, TRIPS, Flexibilities & Access to Medicines –Legal Perspective Lesotho Civil Society Consultation Meeting 12 August 2014.
PATENTS Introduction and International Regime Victor H. Bouganim WCL, American University.
DOMESTICATION OF TRIPS FLEXIBILITIES IN NATIONAL IP LEGISLATION FOR STRENGTHENING ACCESS TO MEDICINES IN ZAMBIA PROPOSED PATENT BILL AND ITS RELEVANCY.
LESOTHO VALIDATION WORKSHOP 25 NOVEMBER 2014 CAILIN MORRISON RECAP – THE INTERNATIONAL CONTEXT: THE WTO, PATENTS, TRIPS FLEXIBILITIES & ACCESS TO MEDICINES.
TRIPS and Public Health: Thailand’s Compulsory Licenses over Patented Drugs for Chronic Diseases December 2, 2013 By Sakda Thanitcul.
Patents, access to medicines and the WTO ’ s TRIPs Agreement Consultative meeting on incorporation of TRIPs Flexibilities Morogoro, Tanzania 24 July 2006.
1 CUTS International Capacity Building Training Programme on Advance IPR, WTO-Related Issues and Patent Writing April 28-May 02, 2008, Jaipur Session 10.
Intellectual Property Rights in the WTO CARSTEN FINK The WTO and the Doha Development Agenda Washington, DC, April 26, 2005.
IBT – Problem 9.3 TRIPS and Pharmaceutical Victor H. Bouganim WCL, American University.
What are the TRIPS flexibilities? How can their incorporation in patent legislation promote access to essential medicines? 25 November 2014, Maseru, Lesotho.
What are the TRIPS flexibilities? How will their incorporation in patent legislation promote access to essential medicines? IP and Access to Medicines:
Page 1 Implementation of the WTO Decision on TRIPS and Public Health Government of Canada August 2004.
The Doha Declaration and the Protocol amending the TRIPS Agreement Islamabad, 28 November 2007 Octavio Espinosa WIPO.
UNCTAD/CD-TFT 1 Exclusive Rights and Public Access – Flexibilities in International Agreements and Development Objectives The Public Health Example 21.
O VERVIEW OF P UBLIC H EALTH -R ELATED TRIPS F LEXIBILITIES Sisule F. Musungu, IQsensato (
Durban, South Africa January 29 to 31, 2013 Topic 17: Research and Regulatory Review Exception Regional Seminar for Certain African Countries on the Implementation.
© 2008 International Intellectual Property June 24, 2009 Class 8 Patents: Multilateral Agreements (WTO TRIPS); Global Problem of Patent Protection for.
Test data protection TRIPS requirements & TRIPS-plus provisions Carlos Correa.
UNCTAD/CD-TFT 1 Basic Features of the Multilateral Systems of Patents and Regulatory Test Data Development Dimensions of Intellectual Property Rights Hanoi.
DOMESTICATION OF TRIPS FLEXIBILITIES IN NATIONAL IP LEGISLATION FOR STRENGTHENING ACCESS TO MEDICINES IN ZAMBIA PROPOSED PATENT BILL AND ITS RELEVANCY.
Data Protection in compliance with Article 39 of the TRIPS Agreement Draft Amendment to the Drugs Act 1976 Humaira Mufti WIPO National Seminar on Flexibilities.
A: Copy –Rights – Artistic, Literary work, Computer software Etc. B: Related Rights – Performers, Phonogram Producers, Broadcasters etc. C: Industrial.
Managing Procurement and Logistics of HIV/AIDS Drugs and Related Supplies By Yvonne Nkrumah Legal Counsel, Ghana Food and Drugs Board.
‘Linkage’ & other TRIPS+ provisions: a public health perspective Karin Timmermans World Health Organization Seminar “Data exclusivity and patent Bangkok.
Trade Related Intellectual Property Agreement John Ries, SPHA511.
South Africa’s Acceptance of the Protocol Amending the TRIPS Agreement Xolelwa Mlumbi- Peter DDG: ITED 24 November 2015.
PATENTS, INTEGRATED CIRCUITS, AND INDUSTRIAL DESIGNS Presented By: Navdeep World Trade Organization.
Intellectual Property and Public Policy: Application of Flexibilities in the International IP and Trade system --Limitation and Exceptions for Education.
Intellectual Property Negotiations Between the United States and Colombia, Peru and Equator for a Free Trade Agreement, Relating to Medicine James Love.
Access v. Patents: We Still Can’t Get Along Srividhya Ragavan University of Oklahoma Law Center.
1 Special mechanism for the importation of pharmaceutical products under the TRIPS Agreement Carlos M. Correa.
International Intellectual Property Prof. Manheim Spring, 2007 Patent Compulsory Licensing Copyright © 2007.
Dialogue on Competition Policy and Intellectual Property *
Overview of presentation
WTO and medicines: from Doha to Cancún
Intellectual Property Protection and Access to Medicines
Susy Frankel Victoria University of Wellington New Zealand
Patent law update.
WIPO NATIONAL SEMINAR ON INTELLECTUAL PROPERTY RIGHTS AND THE PROTECTION OF PHARMACEUTICAL PRODUCTS Damascus, April 25 and 26, 2005 Current issues on Intellectual.
IP Protection under the WTO
Acceptance of the Protocol Amending the TRIPS Agreement
Presentation transcript:

Actions Developing in Countries Accessing the WTO System Vung Tau, February 2006 “US – Brazil Compulsory licensing

IPR or health?  Health of course, but …  1999 US in conflict with several developing countries  Dispute with Brazil referred to DSU (case DS 199)  USA defending investments in R&D – Brazil protecting the right to health services

IPR & medicines  Developing new chemical entities expensive and time consuming  10 – 12 years  Several 100 millions $  Easy to copy  Patent protection required  TRIPS Art 27 (problem/solution)  New  Inventive step  Industrial application  years protection

Generic competition  Generic race to the market  Fair use  For private purposes  For experimental purposes  EU./. Canada (dispute DS 114)  Experiments for registration purposes  Experiments for stock-piling purposes  Rules of interpretation used by the panel

Monopoly pricing  Consequence  monopoly pricing during patent protection.  Exorbitant treatment costs  Solution for the developed - but not the developing world

Compulsory licensing  Compulsory licensing an old concept  Paris Convention  Local production requirement  Not much used  Exception Canada/GB  No US legislation

Article 30 – 31 TRIPS a cumbersome procedure  Article 30 - Exceptions to Rights Conferred  Members may provide limited exceptions  not unreasonably prejudice the legitimate interests of the patent owner,  taking account of the legitimate interests of third parties.  Article 31 - Other Use Without Authorization  (b) prior efforts to obtain authorization on reasonable commercial terms.  Waived in case of national emergency or other circumstances of extreme urgency; …  (f) any such use shall be authorized predominantly for the supply of the domestic market of the Member authorizing such use; …  (h) the right holder shall be paid adequate remuneration; …  (k) anti-competitive practices;

Local production requirement hurdle for LDCs  HIV/AIDS and other epidemic diseases  LDCs have no production capacity  2001 DOHA Declaration  §6.We recognize that WTO Members with insufficient or no manufacturing capacities in the pharmaceutical sector could face difficulties in making effective use of compulsory licensing under the TRIPS Agreement. We instruct the Council for TRIPS to find an expeditious solution to this problem and to report to the General Council before the end of 2002.

Solutions  2003 August 30 Agreement  Problematic discussion  Clinton foundation and MSF  2005 December 6 revision of TRIPS  First revision of a WTO Agreement  Still a cumbersome procedure  Undertakings from developed nations not to abuse the system  Need to get national trade diversion rules in order